search
Back to results

PRP Versus HA IN OSTEOARTHRITIS OF THE PATELLOFEMORAL JOINT

Primary Purpose

Patellofemoral Osteoarthritis

Status
Recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Autologous PRP injection
HA injection
Sponsored by
Istituto Ortopedico Rizzoli
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Patellofemoral Osteoarthritis focused on measuring PRP, HA, Osteoarthritis, Autologous PRP, PRP injection, HA injection, injection treatment, Randomized controlled trial, Hyaluronic Acid, Platelet rich plasma

Eligibility Criteria

30 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age between 30 and 65;
  2. Signs and symptoms of isolated patellofemoral osteoarthritis present in one or both knees;
  3. Radiographic signs of isolated patellofemoral osteoarthritis (according to Iwano et al stage 1-3 classification) or chondropathy (assessed on MRI) with K-L grade of the other compartments ≤ 2. [PMID: 2302884 - PMID: 27979409] ;
  4. Hemoglobin > 11 g/dl; Platelet count > 150,000 plt/mm3 (Recently performed CBC exam);
  5. No clinically significant electrocardiographic alterations (Recently performed ECG).
  6. Ability and consent of patients to actively participate in clinical follow-up;
  7. Signature of informed consent.

Exclusion Criteria:

  1. Patients unable to express consent;
  2. Patients who have undergone intra-articular infiltration of another substance within the previous 6 months;
  3. Patients undergoing knee surgery within the previous 12 months;
  4. Patients with malignant neoplasms;
  5. Patients with rheumatic diseases;
  6. Patients with diabetes;
  7. Patients with hematologic diseases (coagulopathies);
  8. Patients on anticoagulant-antiaggregant therapy;
  9. Patients with thyroid metabolic disorders;
  10. Patients abusing alcoholic beverages, drugs or medications;
  11. Body Mass Index > 35;
  12. Patients who have taken NSAIDs in the 3 days prior to blood draw;
  13. Patients with cardiovascular disease for which a 60 mL blood draw would be contraindicated;
  14. Patients with a recently performed blood test with Hb< 11 g/dl and Platelets < 150,000 plt/mm3.
  15. Previous treatment of patellar dislocation
  16. Iwano score of grade 4.

Sites / Locations

  • Istituto Ortopedico RizzoliRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Autologous PRP injection

HA injection

Arm Description

This group of patients will be treated with single intra-articular injection of Autologous PRP.

This group of patients will be treated with single intra-articular injection of Hyaluronic Acid (HA)

Outcomes

Primary Outcome Measures

KOOS-Pain Score
KOOS-Pain Score is referred to a subscale of pain composed by 9 items. The score range considerate is 0-100.The score uses a 5-point Likert scale and each question is assigned a score from 0 to 4, where 0 indicates "no pain" and 4 "severe level of pain".

Secondary Outcome Measures

IKDC-Subjective Score
This is a subjective, knee-specific rating scale that is considered one of the most reliable assessment tools in the evaluation of knee pathologies. All questions examines 3 categories: symptoms, sports activity, and knee function.
KOOS-Pain Score
KOOS-Pain Score is referred to a subscale of pain composed by 9 items. The score range considerate is 0-100.The score uses a 5-point Likert scale and each question is assigned a score from 0 to 4, where 0 indicates "no pain" and 4 "severe level of pain".
Visual Analogue Scale (VAS)
VAS is a visual analogue scale consisting of a range scale (10 cm length), the ends of which correspond to "no pain" and "the strongest pain imaginable".
EQ-VAS
EQ-VAS Is a visual analog scale that has a range of scores from 0 (worst imaginable health condition) to 100 (best imaginable health condition).
EQ-5D (EuroQoL) Current Health Assessment
EQ-5D is useful to evaluate the quality life of the patients
Tegner Activity Level Scale
Tegner activity level scale allows to know the level of physical activity carried out by the patients. All patients will indicate the type of sporting activity performed and its frequency.
Objective parameters- Range of Motion
Evaluation of the Range of Motion for comparative analysis.
Objective parameters - Circumferences
Bilateral trans- and supra- patellar circumferences measurement for comparative analysis
Patient Acceptable Symptom State (PASS)
A tool to assess patient satisfaction in consideration of their current degree of pain, function, and daily activity. Patients can express if their state of health will be satisfying, answering "yes" or "no.
The Kujala Anterior Knee Pain Scale (AKPS)
It's a 100-point scale consisting of 13 items with a score ranging from 5 to 10 points per item. A score of 0 points indicates the most severe limitation, while a score of 100 points indicates a normal situation.

Full Information

First Posted
June 18, 2021
Last Updated
May 9, 2023
Sponsor
Istituto Ortopedico Rizzoli
search

1. Study Identification

Unique Protocol Identification Number
NCT04937998
Brief Title
PRP Versus HA IN OSTEOARTHRITIS OF THE PATELLOFEMORAL JOINT
Official Title
THE USE OF FRESH PRP VS HA IN THE TREATMENT OF OSTEOARTHRITIS OF THE PATELLOFEMORAL JOINT Randomized Controlled Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 26, 2022 (Actual)
Primary Completion Date
October 2024 (Anticipated)
Study Completion Date
October 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Istituto Ortopedico Rizzoli

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of the study is to compare the 12-month clinical outcomes of patients with patellofemoral osteoarthritis undergoing infiltrative treatment with fresh PRP and HA
Detailed Description
166 patients affected by patellofemoral osteoarthritis will be included in a double-blinded RCT. In this study one group of patients will be treated with 1 intra-articular injection of PRP (treatment arm) and one group will be treated with 1 intra-articular injection of HA (control arm). Patients will be followed-up with clinical evaluation at baseline and at 2.6.12 and 24 months. Questionnaires will be administered for clinical evaluations during the follow-up visits.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Patellofemoral Osteoarthritis
Keywords
PRP, HA, Osteoarthritis, Autologous PRP, PRP injection, HA injection, injection treatment, Randomized controlled trial, Hyaluronic Acid, Platelet rich plasma

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The study is a double-blinded RCT in which one group of patients will be treated with 1 intra-articular injection of fresh PRP, and one group will be treated with 1 intra-articular injection of HA.
Masking
ParticipantOutcomes Assessor
Masking Description
This is a double-blinded randomized controlled trial with 1:1 allocation.Patient blinding will be provided during the injection treatment.
Allocation
Randomized
Enrollment
166 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Autologous PRP injection
Arm Type
Experimental
Arm Description
This group of patients will be treated with single intra-articular injection of Autologous PRP.
Arm Title
HA injection
Arm Type
Active Comparator
Arm Description
This group of patients will be treated with single intra-articular injection of Hyaluronic Acid (HA)
Intervention Type
Procedure
Intervention Name(s)
Autologous PRP injection
Intervention Description
Patients will be treated with a single injection of Autologous PRP (5 ml) in the knee joint affected by patellofemoral osteoarthritis
Intervention Type
Procedure
Intervention Name(s)
HA injection
Intervention Description
Patients will be treated with a single injections of Hyaluronic Acid (5 ml) in the knee joint affected by patellofemoral osteoarthritis
Primary Outcome Measure Information:
Title
KOOS-Pain Score
Description
KOOS-Pain Score is referred to a subscale of pain composed by 9 items. The score range considerate is 0-100.The score uses a 5-point Likert scale and each question is assigned a score from 0 to 4, where 0 indicates "no pain" and 4 "severe level of pain".
Time Frame
12 months
Secondary Outcome Measure Information:
Title
IKDC-Subjective Score
Description
This is a subjective, knee-specific rating scale that is considered one of the most reliable assessment tools in the evaluation of knee pathologies. All questions examines 3 categories: symptoms, sports activity, and knee function.
Time Frame
baseline, 2 month, 6 months, 12 months , 24 months follow-up
Title
KOOS-Pain Score
Description
KOOS-Pain Score is referred to a subscale of pain composed by 9 items. The score range considerate is 0-100.The score uses a 5-point Likert scale and each question is assigned a score from 0 to 4, where 0 indicates "no pain" and 4 "severe level of pain".
Time Frame
baseline, 2 month, 6 months , 24 months follow-up
Title
Visual Analogue Scale (VAS)
Description
VAS is a visual analogue scale consisting of a range scale (10 cm length), the ends of which correspond to "no pain" and "the strongest pain imaginable".
Time Frame
baseline, 2 month, 6 months, 12 months , 24 months follow-up
Title
EQ-VAS
Description
EQ-VAS Is a visual analog scale that has a range of scores from 0 (worst imaginable health condition) to 100 (best imaginable health condition).
Time Frame
baseline, 2 month, 6 months, 12 months , 24 months follow-up
Title
EQ-5D (EuroQoL) Current Health Assessment
Description
EQ-5D is useful to evaluate the quality life of the patients
Time Frame
baseline, 2 month, 6 months, 12 months , 24 months follow-up
Title
Tegner Activity Level Scale
Description
Tegner activity level scale allows to know the level of physical activity carried out by the patients. All patients will indicate the type of sporting activity performed and its frequency.
Time Frame
baseline, 2 month, 6 months, 12 months , 24 months follow-up
Title
Objective parameters- Range of Motion
Description
Evaluation of the Range of Motion for comparative analysis.
Time Frame
baseline, 2 month, 6 months, 12 months , 24 months follow-up
Title
Objective parameters - Circumferences
Description
Bilateral trans- and supra- patellar circumferences measurement for comparative analysis
Time Frame
baseline, 2 month, 6 months, 12 months , 24 months follow-up
Title
Patient Acceptable Symptom State (PASS)
Description
A tool to assess patient satisfaction in consideration of their current degree of pain, function, and daily activity. Patients can express if their state of health will be satisfying, answering "yes" or "no.
Time Frame
baseline, 2 month, 6 months, 12 months , 24 months follow-up
Title
The Kujala Anterior Knee Pain Scale (AKPS)
Description
It's a 100-point scale consisting of 13 items with a score ranging from 5 to 10 points per item. A score of 0 points indicates the most severe limitation, while a score of 100 points indicates a normal situation.
Time Frame
baseline, 2 month, 6 months, 12 months , 24 months follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age between 30 and 65; Signs and symptoms of isolated patellofemoral osteoarthritis present in one or both knees; Radiographic signs of isolated patellofemoral osteoarthritis (according to Iwano et al stage 1-3 classification) or chondropathy (assessed on MRI) with K-L grade of the other compartments ≤ 2. [PMID: 2302884 - PMID: 27979409] ; Hemoglobin > 11 g/dl; Platelet count > 150,000 plt/mm3 (Recently performed CBC exam); No clinically significant electrocardiographic alterations (Recently performed ECG). Ability and consent of patients to actively participate in clinical follow-up; Signature of informed consent. Exclusion Criteria: Patients unable to express consent; Patients who have undergone intra-articular infiltration of another substance within the previous 6 months; Patients undergoing knee surgery within the previous 12 months; Patients with malignant neoplasms; Patients with rheumatic diseases; Patients with diabetes; Patients with hematologic diseases (coagulopathies); Patients on anticoagulant-antiaggregant therapy; Patients with thyroid metabolic disorders; Patients abusing alcoholic beverages, drugs or medications; Body Mass Index > 35; Patients who have taken NSAIDs in the 3 days prior to blood draw; Patients with cardiovascular disease for which a 60 mL blood draw would be contraindicated; Patients with a recently performed blood test with Hb< 11 g/dl and Platelets < 150,000 plt/mm3. Previous treatment of patellar dislocation Iwano score of grade 4.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Roberta Licciardi, MSc
Phone
0516366567
Email
roberta.licciardi@ior.it
First Name & Middle Initial & Last Name or Official Title & Degree
Alessandro Di Martino, MD
Email
alessandro.dimartino@ior.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alessandro Di Martino, MD
Organizational Affiliation
Istituto Ortopedico Rizzoli
Official's Role
Principal Investigator
Facility Information:
Facility Name
Istituto Ortopedico Rizzoli
City
Bologna
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alessandro Di Martino, MD
Phone
6366567
Ext
051
Email
alessandro.dimartino@ior.it
First Name & Middle Initial & Last Name & Degree
Roberta Licciardi, MSc
Phone
6366567
Ext
051
Email
roberta.licciardi@ior.it

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
30545242
Citation
Di Martino A, Di Matteo B, Papio T, Tentoni F, Selleri F, Cenacchi A, Kon E, Filardo G. Platelet-Rich Plasma Versus Hyaluronic Acid Injections for the Treatment of Knee Osteoarthritis: Results at 5 Years of a Double-Blind, Randomized Controlled Trial. Am J Sports Med. 2019 Feb;47(2):347-354. doi: 10.1177/0363546518814532. Epub 2018 Dec 13.
Results Reference
background
PubMed Identifier
16921694
Citation
Everts PA, Knape JT, Weibrich G, Schonberger JP, Hoffmann J, Overdevest EP, Box HA, van Zundert A. Platelet-rich plasma and platelet gel: a review. J Extra Corpor Technol. 2006 Jun;38(2):174-87.
Results Reference
background
PubMed Identifier
24599205
Citation
Cavallo C, Filardo G, Mariani E, Kon E, Marcacci M, Pereira Ruiz MT, Facchini A, Grigolo B. Comparison of platelet-rich plasma formulations for cartilage healing: an in vitro study. J Bone Joint Surg Am. 2014 Mar 5;96(5):423-9. doi: 10.2106/JBJS.M.00726.
Results Reference
background
PubMed Identifier
27979409
Citation
deDeugd CM, Pareek A, Krych AJ, Cummings NM, Dahm DL. Outcomes of Patellofemoral Arthroplasty Based on Radiographic Severity. J Arthroplasty. 2017 Apr;32(4):1137-1142. doi: 10.1016/j.arth.2016.11.006. Epub 2016 Nov 15.
Results Reference
background
PubMed Identifier
24942296
Citation
Assirelli E, Filardo G, Mariani E, Kon E, Roffi A, Vaccaro F, Marcacci M, Facchini A, Pulsatelli L. Effect of two different preparations of platelet-rich plasma on synoviocytes. Knee Surg Sports Traumatol Arthrosc. 2015 Sep;23(9):2690-703. doi: 10.1007/s00167-014-3113-3. Epub 2014 Jun 19.
Results Reference
background

Learn more about this trial

PRP Versus HA IN OSTEOARTHRITIS OF THE PATELLOFEMORAL JOINT

We'll reach out to this number within 24 hrs